For the year ending 2025-12-31, DCOY had $8,275,409 increase in cash & cash equivalents over the period. -$5,404,188 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -12,518,480 |
| Depreciation, amortization and impairment | 7,151 |
| Equity-based compensation | 219,058 |
| Change in fair value of warrant liability | -6,540 |
| In-process research and development expense | 8,517,966 |
| Prepaid expenses and other current assets | -419,628 |
| Accounts payable | -1,167,068 |
| Accrued expenses | -298,903 |
| Net cash used in operating activities | -4,827,188 |
| Issuance of promissory loan in connection with asset acquisition | 577,000 |
| Cash received from asset acquisition, net of cash paid | 1,341,735 |
| Net cash provided by investing activities | 764,735 |
| Proceeds from issuance of equity securities, net | 12,559,728 |
| Payments on note payable | 221,866 |
| Net cash provided by financing activities | 12,337,862 |
| Net increase (decrease) in cash, cash equivalents , and restricted cash | 8,275,409 |
| Cash, cash equivalents and restricted cash at beginning of period | 2,434,528 |
| Cash, cash equivalents and restricted cash at end of period | 10,709,937 |
Decoy Therapeutics Inc. (DCOY)
Decoy Therapeutics Inc. (DCOY)